Fertility Test Market

Global Fertility Test Market Size

The size of the global fertility test market was worth USD 696.14 million in 2025. The global market is anticipated to grow at a CAGR of 8.1% from 2026 to 2034 and be worth USD 1,403 million by 2034 from USD 752.53 million in 2026.

The fertility test is a diagnostic tool and service designed to evaluate the reproductive health of both men and women, identifying potential barriers to conception. These diagnostics range from at-home ovulation predictor kits and sperm analysis devices to sophisticated clinical assessments involving hormonal profiling, genetic screening, and imaging technologies. According to the World Health Organization, approximately 17.5% of the adult population globally experiences infertility, translating to roughly one in six people who require medical assistance to conceive. Furthermore, demographic shifts toward delayed parenthood have intensified the urgency for early detection of reproductive issues. Data from Eurostat indicates that the mean age of women at first childbirth in the European Union reached 30.9 years in 2023, a trend that correlates strongly with increased risks of age-related fertility decline. As individuals postpone family formation, the reliance on precise testing to assess ovarian reserve and sperm quality becomes paramount. The integration of advanced technologies, such as artificial intelligence in image analysis and microfluidics in home testing devices, is further transforming the landscape, making diagnostics more user-friendly and reliable. These epidemiological and technological factors establish a robust foundation for the expansion of the fertility testing ecosystem.

MARKET DRIVERS

Increasing Prevalence of Infertility Due to Lifestyle Changes and Delayed Parenthood

The escalating global incidence of infertility driven by modern lifestyle factors and the societal trend of delaying childbearing is propelling the growth of the fertility test market. Factors such as chronic stress, poor dietary habits, obesity, and exposure to environmental toxins have significantly impaired reproductive health across genders. According to the Centers for Disease Control and Prevention, about 12% of women aged 15 to 44 in the United States struggle with impaired fecundity, creating a vast pool of individuals seeking diagnostic clarity. The biological reality is that female fertility declines sharply after the age of 35, yet the average age of first-time mothers continues to rise in developed nations. The European Society of Human Reproduction and Embryology reports that advanced maternal age is now the leading cause of infertility in Europe, necessitating comprehensive testing to evaluate ovarian reserve through markers like Anti-Mullerian Hormone. Similarly, male factor infertility accounts for approximately 40 to 50% of all infertility cases, often linked to sedentary lifestyles and heat exposure. The World Health Organization notes that sperm counts have dropped by over 50% in the last four decades, driving demand for accessible sperm analysis. As couples increasingly recognize these risks, the proactive adoption of fertility tests to determine reproductive windows and identify underlying issues has become a standard practice, fueling sustained market growth.

Technological Advancements in At-Home Diagnostic Devices and Digital Health Integration

The rapid evolution of at-home fertility testing technologies, coupled with the integration of digital health platforms that enhance user experience and data accuracy, is also driving the growth of the fertility test market. Traditional clinical testing often involves invasive procedures, long wait times, and high costs, creating barriers to access. Modern innovations have introduced non-invasive, user-friendly devices capable of measuring key biomarkers such as luteinizing hormone, estradiol, and progesterone directly from urine or saliva with clinical-grade precision. As per data from the Consumer Technology Association, the shipment of connected health devices has surged, with fertility trackers representing a significant portion of this growth. These devices often sync with smartphone applications that use algorithms to predict fertile windows and provide personalized insights, empowering users to manage their reproductive health proactively. The Food and Drug Administration has cleared numerous digital fertility tools, validating their efficacy and boosting consumer confidence. Furthermore, the advent of microfluidics and smartphone-based microscopy allows for detailed sperm analysis at home, a capability previously restricted to laboratories. The American Society for Reproductive Medicine highlights that telehealth integration enables remote consultation with specialists based on home test results, streamlining the care pathway.

MARKET RESTRAINTS

High Cost of Advanced Diagnostic Procedures and Limited Insurance Coverage

The substantial financial burden associated with advanced diagnostic procedures and the inconsistent coverage provided by insurance plans are two of the major factors limiting the growth of the fertility test market. While basic ovulation kits are affordable, comprehensive fertility workups involving hormonal panels, genetic screening, and specialized imaging can cost thousands of dollars, placing them out of reach for many individuals. According to the National Conference of State Legislatures, only 19 states in the United States have laws mandating some level of insurance coverage for infertility diagnosis and treatment, leaving a large majority of patients to bear the full cost out of pocket. In Europe, coverage varies widely between countries, with some national health systems covering only basic tests while excluding advanced genetic or immunological assessments. The World Bank notes that out-of-pocket health expenditure remains a major barrier to accessing reproductive care in low and middle-income countries, where fertility testing is often viewed as a luxury rather than a medical necessity. This financial disparity limits market penetration, particularly among younger demographics and underserved populations who may benefit most from early detection.

Social Stigma and Psychological Barriers Surrounding Infertility Testing

The persistent social stigma and psychological distress associated with infertility, which often deters individuals from seeking diagnostic evaluation is additionally hampering the growth of the fertility test market. In many cultures, infertility is wrongly perceived as a personal failure or a source of shame, leading couples to delay or avoid testing altogether. As per findings from the International Federation of Fertility Societies, the emotional toll of infertility can lead to anxiety, depression, and relationship strain, causing individuals to suppress their desire for children rather than confront potential diagnoses. This silence is particularly pronounced in male infertility, where societal expectations of masculinity often prevent men from undergoing sperm analysis. The World Health Organization emphasizes that stigma acts as a barrier to healthcare-seeking behavior, resulting in late diagnoses when treatment options are more limited and expensive. Furthermore, the fear of receiving a negative diagnosis can paralyze decision-making, with many individuals preferring uncertainty over the potential heartbreak of confirmed infertility. Educational campaigns have made strides in raising awareness, but deep-seated cultural norms continue to inhibit open discussion and proactive testing.

MARKET OPPORTUNITIES

Expansion of Male Fertility Testing and Awareness Campaigns

The burgeoning focus on male reproductive health to expand into the historically underserved segment of male fertility testing is significantly boosting the growth of the fertility test market. Traditionally, fertility evaluations have disproportionately focused on women, despite male factors contributing to nearly half of all infertility cases. There is a growing recognition among clinicians and patients of the need for routine sperm analysis as a first-line diagnostic tool. According to the American Urological Association, increasing awareness campaigns are encouraging men to view fertility testing as a standard part of preconception care, similar to women's health checks. The development of discreet, at-home sperm testing kits that provide rapid results via smartphone apps has lowered the barrier to entry, making testing more accessible and less intimidating. The Global Men's Health Forum highlights that early detection of male infertility can lead to simpler, less invasive treatments and improved outcomes for couples. Companies that innovate in this space by offering comprehensive male hormonal profiles and genetic screening alongside basic sperm counts stand to capture a significant share.

Integration of Artificial Intelligence and Predictive Analytics in Fertility Care

The integration of artificial intelligence and predictive analytics into fertility testing platforms to enhance diagnostic accuracy and personalize treatment recommendations is also expected to level up the growth of the fertility test market. AI algorithms can analyze vast datasets from hormonal cycles, lifestyle factors, and historical test results to predict fertility potential with unprecedented precision. As per research published in Nature Medicine, machine learning models have demonstrated superior ability in interpreting ultrasound images for ovarian follicle counting and predicting IVF success rates compared to human experts. This capability allows for earlier identification of conditions like polycystic ovary syndrome and endometriosis, enabling timely intervention. The Bill and Melinda Gates Foundation supports initiatives leveraging AI to improve reproductive health outcomes in resource-limited settings, indicating global potential. Furthermore, predictive analytics can guide users on optimal timing for conception or egg freezing, adding significant value to consumer-facing apps and devices. The Federal Trade Commission notes that consumers are increasingly willing to share health data for personalized insights, driving the adoption of AI-enabled platforms.

MARKET CHALLENGES

Regulatory Complexity and Variability in Approval Pathways for Diagnostic Devices

The complexity in governing the approval of diagnostic devices, particularly those marketed for home use, is acting as a barrier to the growth of the fertility test market. Regulatory bodies such as the Food and Drug Administration in the United States and the European Medicines Agency in Europe have stringent requirements for demonstrating the clinical validity and reliability of fertility tests, especially those claiming to predict ovulation or assess sperm quality. Manufacturers must conduct extensive clinical trials to prove that their devices perform equivalently to laboratory standards, a process that is both time-consuming and costly. The transition to the Medical Device Regulation in Europe has further tightened these requirements, demanding robust post-market surveillance and clinical evidence. The variability in regulations across different jurisdictions complicates global product launches, forcing companies to navigate a patchwork of compliance standards. Additionally, the classification of digital health apps and AI-driven diagnostics remains evolving, creating uncertainty for innovators. The delay in obtaining clearances can result in missed market windows and reduced return on investment.

Accuracy Limitations and User Error in At-Home Testing Kits

The accuracy limitations of certain at-home testing kits and the potential for user error, which can lead to misleading results and emotional distress is likely to degrade the growth of the fertility test market. While technology has improved, factors such as improper sample collection, timing errors, and interference from medications or underlying health conditions can compromise the reliability of home tests. According to studies published in the Journal of Assisted Reproduction and Genetics, false negatives in ovulation prediction can cause couples to miss their fertile window, while false positives may lead to unnecessary anxiety or delayed medical consultation. The complexity of interpreting results, particularly with colorimetric strips or microscopic images, poses difficulties for users without medical training. The Centers for Disease Control and Prevention emphasizes that without proper counseling, individuals may misinterpret test outcomes, leading to inappropriate self-management of fertility issues. Furthermore, the lack of standardized quality control across the burgeoning market of direct-to-consumer tests means that performance can vary widely between brands. This inconsistency erodes consumer trust and may discourage repeat usage.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Testing Device Insights

The ovulation predictor kit segment was the largest by holding 45.3% of the global fertility test market share in 2025, owing to the high level of consumer awareness regarding the importance of timing intercourse with ovulation to maximize conception chances. These kits detect the surge in luteinizing hormone that precedes ovulation, providing a clear window for fertility. According to the American Society for Reproductive Medicine, timing intercourse during the fertile window can increase the probability of conception by up to 30% compared to random timing, making these kits an essential tool for couples trying to conceive. The simplicity of urine-based testing allows women to perform tests at home with privacy and convenience, removing the barrier of clinic visits. Data from the Centers for Disease Control and Prevention indicates that over 80% of couples attempting to conceive will do so successfully within one year, often aided by basic tracking methods like ovulation kits. The widespread availability of these kits in pharmacies, supermarkets, and online retailers ensures that they are the default choice for initial fertility assessment.

The male fertility testing products segment is projected to expand at a CAGR of 12.8% during the forecast period, with the growing clinical and public acknowledgment that male factors contribute to approximately 40 to 50% of all infertility cases, necessitating equal focus on male diagnostics. Historically, fertility evaluations disproportionately targeted women, but modern guidelines now recommend simultaneous testing of both partners. According to the American Urological Association, early evaluation of male fertility can identify treatable conditions such as varicoceles or hormonal imbalances, improving overall treatment outcomes for couples. The World Health Organization reports that sperm counts have declined by more than 50% over the past four decades, raising alarm and prompting more men to seek testing. This shift in perspective is driving demand for accessible male testing solutions. Educational campaigns by organizations like the Men's Health Network are destigmatizing male infertility, encouraging men to take proactive steps.

By Mode of Purchase Insights

The non-prescription or over-the-counter segment was expected to hold a dominant share of the global fertility test market in 2025, with the strong consumer preference for privacy and convenience when addressing sensitive reproductive health issues. Many individuals feel uncomfortable discussing fertility struggles with healthcare providers immediately and prefer to gather initial data privately at home. According to a survey by the Pew Research Center, a significant majority of adults prefer to manage minor health concerns independently before seeking professional help, a trend that extends strongly to fertility testing. The ability to purchase tests at local pharmacies, grocery stores, or online retailers without a doctor's visit empowers users to control their reproductive journey on their own terms. The Centers for Disease Control and Prevention notes that early detection through home testing can prompt timely medical consultation, but the initial step is often taken independently.

The prescription-based segment is likely to register the fastest CAGR of 9.5% from 2026 to 2034, with the rapid growth of the prescription segment is the rising demand for sophisticated diagnostic tests that require clinical expertise for administration and interpretation, such as genetic carrier screening and comprehensive hormonal panels. As reproductive medicine advances, simple ovulation detection is often insufficient for couples facing recurrent pregnancy loss or unexplained infertility, necessitating deeper investigation. According to the American College of Obstetricians and Gynecologists, genetic screening for conditions like cystic fibrosis or fragile X syndrome is increasingly recommended preconception, requiring physician orders and counseling. These complex tests involve blood draws and specialized laboratory analysis that cannot be performed at home. The National Institutes of Health highlights that identifying specific genetic markers can guide personalized treatment plans and improve IVF success rates.

By Application Insights

The female fertility testing segment is expected to hold a dominant share of the global fertility test market in 2025, owing to the intricate nature of the female reproductive system, which involves a complex interplay of hormones, anatomical structures, and cyclical changes that require multifaceted diagnostic approaches. According to the Mayo Clinic, female factors account for about one-third of infertility cases, with another third attributed to combined male and female factors, highlighting the critical need for comprehensive female evaluation. Tests range from simple urine strips for luteinizing hormone to complex blood assays for Anti-Mullerian Hormone, follicle-stimulating hormone, and estradiol, as well as imaging techniques like hysterosalpingography. The American Society for Reproductive Medicine emphasizes that evaluating ovarian reserve and tubal patency is essential for determining fertility potential. The sheer variety of parameters that must be assessed in women creates a larger market for diagnostic products compared to the more singular focus of male testing.

The male fertility testing segment is anticipated to expand at a CAGR of 13.2% during the forecast period. The growth of the segment is majorly driven by the fundamental shift in clinical guidelines that now advocate for the simultaneous evaluation of both partners at the onset of fertility investigations. Modern protocols recognize that delaying male testing wastes valuable time and resources, given that male factors are responsible for nearly half of all infertility cases. According to the European Association of Urology, updated guidelines explicitly recommend semen analysis as a first-line test for all couples presenting with infertility, regardless of female history. The American Society for Reproductive Medicine supports this concurrent approach, noting that early identification of male issues can streamline treatment decisions and improve success rates. This change in clinical practice is driving a surge in the volume of male tests ordered by physicians and purchased by consumers. The realization that male fertility is not static and can be influenced by lifestyle and environmental factors encourages repeated testing and monitoring.

By End User Insights

The Hospitals, Fertility Clinics, and Others segment held a prominent share of the global fertility test market in 2025, with the need for sophisticated diagnostic technologies and expert medical interpretation that are only available in clinical settings. While basic ovulation tests can be done at home, comprehensive fertility assessments involving transvaginal ultrasounds, hysterosalpingography, and complex hormonal assays require specialized equipment and trained personnel. According to the Society for Assisted Reproductive Technology, the success of treatments like IVF depends heavily on accurate baseline diagnostics performed in clinics to tailor stimulation protocols. The American College of Obstetricians and Gynecologists emphasizes that interpreting results for conditions like endometriosis or tubal blockage requires clinical expertise to avoid misdiagnosis and ensure appropriate treatment planning. Patients rely on clinics to provide a holistic evaluation that integrates multiple test results into a coherent diagnosis. The presence of embryologists, reproductive endocrinologists, and radiologists in these settings ensures high accuracy and reliability.

The home care settings segment is projected to register a CAGR of 11.4% in the coming years, with the technological advancement of at-home fertility testing devices that now offer accuracy comparable to clinical tests, coupled with seamless digital integration. Innovations in microfluidics, smartphone connectivity, and AI-driven analysis have empowered consumers to perform reliable tests in the privacy of their homes. According to the Consumer Technology Association, shipments of connected fertility monitors and smart sperm testers have grown in double digits annually, reflecting strong consumer adoption. The Food and Drug Administration clearance of various home diagnostic kits has validated their clinical utility, encouraging wider use. These devices often sync with mobile apps that track cycles, predict fertile windows, and even provide preliminary interpretations of results, creating a comprehensive home diagnostic ecosystem. The National Institutes of Health highlights that home testing reduces the burden on healthcare facilities and allows for more frequent monitoring, which can improve conception chances. The convenience of testing on one's own schedule without travel or waiting rooms appeals to busy lifestyles.

REGIONAL ANALYSIS

North America Fertility Test Market Analysis

North America was the largest contributor in the global fertility test market by holding 38.4% of the share in 2025, owing to the United States, which boasts the highest concentration of advanced fertility clinics, robust consumer awareness, and a thriving market for innovative at-home diagnostic devices. The rising average age of first-time mothers has increased the prevalence of age-related infertility and the subsequent demand for diagnostic testing. According to the Centers for Disease Control and Prevention, the mean age of mothers at first birth in the US has reached record highs, correlating with increased utilization of fertility services. Furthermore, the presence of major market players and a supportive regulatory environment for digital health innovations fosters rapid product launches. The varying insurance coverage landscape drives both OTC and prescription segments, as patients navigate costs. High levels of education and awareness regarding male and female fertility factors also contribute to early and frequent testing.

Europe Fertility Test Market Analysis

Europe fertility test market was ranked second by holding 27.3% of the share in 2025, with a diverse mix of publicly funded healthcare systems in Western Europe and growing private sectors in Eastern Europe, all contributing to steady demand. The low fertility rate across the continent, which has prompted governments to invest heavily in fertility awareness and access to diagnostics. According to Eurostat, the total fertility rate in the EU remains well below the replacement level, driving policy interventions that facilitate access to testing and treatment. Additionally, the aging population and delayed parenthood trends similar to those in North America create a sustained demand for ovarian reserve testing and sperm analysis. The European Society of Human Reproduction and Embryology actively promotes guidelines that encourage early evaluation of both partners. Furthermore, increasing acceptance of at-home testing devices and the expansion of telehealth services are broadening access to diagnostics.

Asia-Pacific Fertility Test Market Analysis

The Asia-Pacific fertility test market is expected to grow at the fastest CAGR in the coming years with the rapid urbanization, changing social norms regarding marriage and childbearing, and increasing investment in healthcare infrastructure. The massive population base, combined with a sharp rise in infertility rates due to lifestyle changes, pollution, and delayed marriages in countries like China, India, and Japan. As per reports from the World Health Organization, infertility affects a significant portion of couples in Asia, yet awareness and access to diagnostics have historically been low, creating a vast untapped market. Governments in the region are increasingly recognizing the demographic crisis of low birth rates and are implementing policies to support fertility treatments and diagnostics. The growing middle class is willing to spend on premium healthcare services, including advanced fertility testing. Local manufacturing initiatives are making tests more affordable, while the penetration of smartphones drives the adoption of digital fertility trackers.

Latin America Fertility Test Market Analysis

Latin America fertility test market growth is likely to grow with a blend of cultural emphasis on family, growing private healthcare sectors, and increasing awareness of reproductive health issues. The market status is evolving, with a gradual shift from traditional remedies to modern diagnostic methods driven by urbanization and education. A major driving factor is the rising prevalence of infertility linked to lifestyle factors such as obesity and stress, alongside the trend of delayed childbearing in urban centers like São Paulo and Mexico City. According to the Pan American Health Organization, access to reproductive health services is improving, though disparities remain between public and private sectors. The strong cultural value placed on having children drives individuals to seek diagnostic answers despite economic challenges. The expansion of private insurance coverage and the presence of international fertility clinic chains are enhancing access to advanced testing. Furthermore, increasing internet penetration is facilitating the sale of OTC fertility tests and the use of digital health apps.

Middle East and Africa Fertility Test Market Analysis

The Middle East and Africa fertility test market growth is propelled by the high prevalence of infertility, partly due to genetic factors and consanguineous marriages, coupled with a strong cultural imperative to have children. As per data from regional health ministries, countries like Saudi Arabia and the UAE have invested heavily in specialized fertility centers, creating a niche but high-value market for diagnostic tests. In Africa, the market is driven by grassroots initiatives and international aid programs aiming to improve maternal and reproductive health, though access to advanced diagnostics remains limited. The World Health Organization notes that infertility is a major public health issue in sub-Saharan Africa, often stigmatized, yet awareness campaigns are beginning to shift perceptions. The growing adoption of mobile health technologies offers a unique opportunity to bypass infrastructure gaps and deliver fertility information and basic testing solutions.

COMPETITIVE LANDSCAPE

The competition within the fertility test market is characterized by intense rivalry between established medical device corporations and agile direct-to-consumer startups striving to redefine accessibility and user experience. Major competitors differentiate themselves through the accuracy of their diagnostic algorithms, the sophistication of their digital health integrations, and the breadth of their testing portfolios covering both male and female factors. The landscape features a constant race to develop non-invasive at-home testing solutions that offer clinical-grade reliability while maintaining privacy and convenience for users. Companies frequently engage in strategic collaborations with reproductive health organizations to validate their technologies and promote awareness of fertility issues. Pricing pressure from generic manufacturers and the availability of basic, low-cost tests compel premium brands to demonstrate superior value through advanced features and comprehensive support services. The shift toward personalized medicine has further intensified competition as vendors strive to offer tailored insights based on individual biological data and lifestyle factors.

MARKET KEY PLAYERS

Notable companies leading the global fertility test market profiled in this report are

• Advacare Pharma
• CooperSurgical Inc
• AVA
• Babystart
• Biozhena
• Church & Dwight (US)
• Fairhaven Health
• Fertility Focus
• Geratherm Medical
• Hilin Life Products
• Procter & Gamble Health Limited
• Prestige Brands Holdings (A Part of Gregory Pharmaceutical Holdings) (US)
• Sensiia
• Swiss Precision Diagnostics (SPD) (Switzerland)
• Taidoc
• Uebe Medical
• Valley Electronics
• Quest Diagnostics

TOP PLAYERS IN THE MARKET

• CooperSurgical Inc stands as a global leader dedicated exclusively to advancing fertility and women's health through innovative diagnostic solutions and clinical products. The company offers a comprehensive portfolio ranging from advanced ovulation predictor kits to sophisticated laboratory equipment for assisted reproductive technologies. CooperSurgical recently strengthened its market position by acquiring key biotechnology firms to expand its genetic screening capabilities and enhance its preconception care offerings. The firm actively collaborates with fertility clinics worldwide to integrate digital health tools that streamline patient monitoring and data analysis. By focusing on evidence-based medicine and continuous product innovation, CooperSurgical ensures it remains at the forefront of reproductive health. Their commitment to improving clinical outcomes and patient experiences drives their strategic initiatives and solidifies their role as a pivotal contributor to the global fertility testing ecosystem without relying on static market metrics.
• Procter & Gamble Health Limited maintains a dominant presence in the consumer fertility testing sector primarily through its renowned Clearblue brand, which is synonymous with home ovulation and pregnancy diagnostics. The company leverages its extensive global distribution network and deep consumer insights to make fertility testing accessible and user-friendly for millions of individuals. Recent actions include the launch of next-generation digital fertility monitors that connect to smartphone applications to provide personalized cycle tracking and fertile window predictions. Procter & Gamble has also invested heavily in marketing campaigns aimed at destigmatizing infertility and encouraging early testing among younger demographics. The organization prioritizes research and development to improve the accuracy and ease of use of its lateral flow assays.
• Quest Diagnostics Incorporated operates as a major contributor to the fertility test market by providing comprehensive clinical laboratory services that include advanced hormonal profiling and genetic carrier screening for prospective parents. The company utilizes its vast network of patient service centers and logistics infrastructure to deliver high-quality diagnostic results to physicians and patients across the globe. Recent efforts by Quest Diagnostics have centered on expanding its menu of fertility-related tests to include specialized assessments for recurrent pregnancy loss and male factor infertility. The firm has launched integrated digital platforms that allow patients to access their results securely and consult with healthcare providers remotely. Additionally, Quest Diagnostics actively partners with fertility clinics and insurance payers to develop value-based care models that improve access to essential diagnostics.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

Key players in the fertility test market primarily employ strategies focused on product innovation and strategic acquisitions to expand their portfolios and capture emerging opportunities. Companies heavily invest in research and development to create advanced digital fertility monitors and accurate at-home sperm analysis kits that appeal to tech-savvy consumers. Mergers and acquisitions allow larger entities to absorb specialized technologies in genetic screening or reproductive biology to broaden their service offerings rapidly. Another prevalent strategy involves forming strategic partnerships with telehealth providers and fertility clinics to create seamless care pathways from testing to treatment. Manufacturers also focus on extensive consumer education campaigns to reduce stigma and encourage early diagnosis among both men and women. Enhancing mobile application integration for real-time data tracking and personalized insights is a critical priority to increase user engagement and retention. Furthermore, companies are increasingly pursuing regulatory approvals in new geographic regions to facilitate global expansion. These combined efforts enable market participants to strengthen their positions and address the evolving needs of individuals seeking reproductive assistance effectively.

MARKET SEGMENTATION

This research report on the global fertility test market has been segmented and sub-segmented into the following categories.

By Testing Device

• Ovulation Predictor Kits
• Fertility Monitors
  • Urine-based Monitors
  • Saliva-based Monitors
  • Other Fertility Monitors
• Male Fertility Testing Products

By Mode of Purchase

• Non-Prescription/OTC-based
• Prescription-based

By Application

• Female Fertility Testing
• Male Fertility Testing

By End User

• Home care settings
• Hospitals, Fertility Clinics, & Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa